Survival Outcomes in the Lurbinectedin vs. Topotecan Trial
Lurbinectedin improved overall survival compared to topotecan, the standard chemotherapy for relapsed small cell lung cancer (SCLC). In the phase III ATLANTIS trial (n=421 patients), median overall survival was 9.3 months with lurbinectedin plus doxorubicin versus 5.9 months with topotecan (hazard ratio [HR] 0.75; 95% CI 0.59-0.95; p=0.0165).[1][2] Progression-free survival also favored lurbinectedin (median 4.0 vs. 3.0 months; HR 0.69; p=0.0013).[1]
This trial targeted sensitive relapsed SCLC after platinum-based first-line therapy. Lurbinectedin received accelerated FDA approval in 2020 for this setting, based on earlier response rates.[3]
How It Compares to Other Standard Chemo Options
Topotecan is the main approved comparator, but real-world SCLC relapse often uses CAV (cyclophosphamide, doxorubicin, vincristine). No head-to-head trials exist against CAV. Lurbinectedin's HR of 0.75 suggests a 25% reduction in death risk over topotecan, but cross-trial data show topotecan OS around 6-8 months versus CAV's 6-10 months in similar patients—differences often not statistically significant.[4][5]
| Regimen | Median OS (months) | Key Trial Population |
|---------|---------------------|----------------------|
| Lurbinectedin + doxorubicin | 9.3 | Sensitive relapse (ATLANTIS)[1] |
| Topotecan | 5.9 | Same (ATLANTIS)[1] |
| Topotecan (historical) | 6.7-8.0 | Sensitive relapse[4] |
| CAV | 6.0-10.3 | Relapse (various)[5] |
Lurbinectedin showed better tolerability, with fewer severe hematologic toxicities (e.g., grade 3/4 neutropenia: 52% vs. 84%).[1]
Why Survival Benefit Isn't Larger
The gain (3.4 months median OS) reflects SCLC's aggressive nature—most patients progress quickly post-platinum. Benefit was consistent across subgroups like age and prior immunotherapy, but smaller in refractory disease (HR 0.96, non-significant).[1][2] No OS data yet combines lurbinectedin with immunotherapy like atezolizumab, though ongoing trials explore this.[6]
Patient and Real-World Factors
Patients report less fatigue and myelosuppression with lurbinectedin, potentially aiding quality of life during extended survival.[7] Cost is higher (list ~$18,000/cycle vs. generic topotecan ~$1,000-2,000), but Medicare coverage applies.[8] No patents block generics yet—lurbinectedin's composition patent (US 7,601,841) expires 2025.[9]
Sources
[1]: Trigo et al., Lancet Oncol 2021
[2]: FDA Approval Summary
[3]: ASCO Post
[4]: O'Brien et al., J Clin Oncol 2006
[5]: Slotman et al., NEJM 2024 meta-analysis
[6]: ClinicalTrials.gov NCT04628880
[7]: Patient-reported outcomes in ATLANTIS
[8]: GoodRx pricing data
[9]: DrugPatentWatch.com - Lurbinectedin